Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

ns with several other parties regarding similar collaborations are ongoing. If successful, these collaborations could lead to these parties taking a licence to Silence delivery technologies.

Potential News Flow Events 2012-2014

In the near and medium term, the Directors believe there is the possibility of multiple potential news flow events from the existing product portfolio of programme deals, and opportunities within the RNAi technology platform, that could, dependent on success, act as value creation points for the business. The indicative dates are the Company's estimates, however no assurance can be given that the various events will be achieved by those dates, or indeed at all.

Internal Product Portfolio

Atu027 (treatment of solid tumours)

  • Completion of Phase I trial of Atu027 (July 2012)
  • Final Phase I results of Atu027 (third quarter of 2012)
  • Initiation of Phase Ib trial (end of 2012/early 2013)
  • Completion of Phase Ib trial (2014)

Atu111 (treatment of acute lung injury)

  • Completion of further proof-of-concept pre-clinical models (end 2012)

Partnered Product Portfolio

PF-'655 (diabetic macular oedema, glaucoma and age-related macular degeneration)

  • Completion of Phase IIb MATISSE study (2014)
  • Initiation of Phase IIa trial in glaucoma (trial start date not yet disclosed by Quark)

QPI-1002 (acute kidney injury 'AKI' and prevention of delayed graft function 'DGF')

  • Completion of Phase II trial in prevention of delayed graft function (second half of 2012)
  • Potential milestone payment upon Novartis' exercise of a license (2013)

Related Party Transaction

As part of the Fundraising, the Directors propose to issue 200,000,000 Subscription
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open ... the pain management and clinical markets. The software increases ... by allowing users to highlight and review results that ... allows analysts to filter results by group or based ... eliminating the need to sift through analytes of no ...
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
... , , BASKING RIDGE, N.J., Sept. 3 ... of antithrombotic aptamers with active control agents, announced today that ... be presenting at the 11th Annual Healthcare Conference of the ... at 4:30 PM on Thursday, September 10, 2009 (EDT). ...
... , ANNAPOLIS, Md., Sept. 3 PharmAthene, ... developing medical countermeasures against biological and chemical threats, announced today ... (rPA) anthrax vaccine program and its Valortim((R)) anthrax anti-toxin program ... 30 - September 3, 2009, organized by the American Society ...
... Global ... , ... September 3, 2009 -- Global animal health company, Alltech was featured as one ... and selling natural animal feed supplements with their 2008 revenues exceeding $400,000,000. It is ...
Cached Biology Technology:Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009 2PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 2PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 3PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 4PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 5PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 6PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 7PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 8PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference 9Alltech Breaks Through: Named Top Green Company by Inc. Magazine 2
(Date:10/18/2014)... of 2,000 patients referred for evaluation of suspected ... diagnosis for 25 percent, including detection of a ... contributing to disease, according to a study appearing ... released to coincide with the American Society of ... the exons or coding regions of thousands of ...
(Date:10/17/2014)... German . ... in order to reproduce? And why are there two sexes ... latest issue of the research journal Molecular Human Reproduction ... Ramm from Bielefeld University Bielefeld has compiled this special issue ... a female to copulate with several males in quick succession ...
(Date:10/16/2014)... wages war on the human body. Battles are ... In pancreatic cancer, this stalemate—known as tumor dormancy—can ... malignant, a phenomena that is poorly understood. ... laboratory of Salvatore Torquato, a Professor of Chemistry ... surrounding tumor dormancy and the switch to a ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... mushroom (Agaricus bisporus) has as much, and in some cases, ... button mushroom is the foremost cultivated edible mushroom in the ... is often thought of as a poor relation to its ... nutritionally. But according to new research in SCIs Journal ...
... Fan Meng of China, a visionary leader who ... in Chinas rapidly industrializing Guangdong Province, has been awarded ... use the Fellowship to expand and improve the regions ... from the serious threats of industrial pollution and unsustainable ...
... to distinguish between the majority of plant species on Earth ... the Proceedings of the National Academy of Sciences journal today ... used to identify plants using a small sample, could lead ... in species-rich areas like rainforests. It could also lead to ...
Cached Biology News:2008 Pew Fellowship in Marine Conservation awarded to Fan Meng; first Chinese fellow 22008 Pew Fellowship in Marine Conservation awarded to Fan Meng; first Chinese fellow 3DNA 'barcode' identified for plants 2DNA 'barcode' identified for plants 3
Request Info...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Biology Products: